在中国患有良性妇科疾病的女性中，血清人附睾蛋白4作为生物标志物比癌抗原125更合适。
Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
作者信息
Zhang Yan, Qiao Chunxia, Li Lian, Zhao Xuye, Li Yali
机构信息
Department of Gynecology and Obstetrics, the Chinese PLA General Hospital.
Laboratory of Immunology, Institute of Basic Medical Sciences.
出版信息
Afr Health Sci. 2014 Dec;14(4):913-8. doi: 10.4314/ahs.v14i4.20.
Abstract
OBJECTIVE
This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign gynecological disorders.
MATERIAL AND METHODS
Sera were obtained from Chinese women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with HE4 and CA125 levels were compared.
RESULTS
There were 68 Chinese women with benign diseases. HE4 levels were less elevated than CA125 (1% V.S. 29%, P<0.001). The significant difference was observed in patients with endometriosis/endometriomas in which HE4 was not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with cystadenoma (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001).
CONCLUSION
HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.
摘要
目的
本研究测定了患有良性妇科疾病的中国女性的附睾蛋白4（HE4）和CA125水平。
材料与方法
采集中国女性盆腔肿块手术前的血清，测定HE4和CA125水平。比较HE4和CA125水平升高的患者比例。
结果
有68名患有良性疾病的中国女性。HE4水平升高的比例低于CA125（1%对29%，P<0.001）。在子宫内膜异位症/子宫内膜瘤患者中观察到显著差异，其中HE4未升高的患者中CA125升高的比例为53%（P<0.001）。囊腺瘤患者（0%对23%，P<0.001）和生殖细胞肿瘤患者（0%对5%，P<0.001）的血清HE4水平未升高。
结论
在患有良性疾病的中国女性中，HE4升高程度较低，比CA125更适合作为生物标志物。
相似文献
1
Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.在中国患有良性妇科疾病的女性中，血清人附睾蛋白4作为生物标志物比癌抗原125更合适。
Afr Health Sci. 2014 Dec;14(4):913-8. doi: 10.4314/ahs.v14i4.20.
2
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.在患有良性妇科疾病的女性中，血清 HE4 水平升高的频率低于 CA125。
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8. doi: 10.1016/j.ajog.2011.12.029. Epub 2011 Dec 30.
3
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.HE4 评估与 CA125 比较在卵巢癌诊断和治疗反应评估中的意义。
Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.
4
HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.用于鉴别诊断良性妇科疾病和卵巢癌的HE4、Ca125及ROMA算法
Tumour Biol. 2014 Jul;35(7):7249-58. doi: 10.1007/s13277-014-1945-6. Epub 2014 Apr 27.
5
HE4 combined with CA125: favorable screening tool for ovarian cancer.HE4 联合 CA125：卵巢癌的有利筛查工具。
Med Oncol. 2014 Jan;31(1):808. doi: 10.1007/s12032-013-0808-0. Epub 2013 Dec 10.
6
Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass.血清HE4和CA125作为绝经前良性盆腔肿块女性肿瘤标志物的比较
Clin Lab. 2019 May 1;65(5). doi: 10.7754/Clin.Lab.2018.180913.
7
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.一种多重生物标志物检测方法提高了 HE4 和 CA125 在卵巢肿瘤患者中的诊断性能。
PLoS One. 2020 Oct 19;15(10):e0240418. doi: 10.1371/journal.pone.0240418. eCollection 2020.
8
The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.血清 HE4 在 CA125 升高的卵巢疾病中的鉴别诊断价值及临床意义。
Arch Gynecol Obstet. 2020 May;301(5):1219-1225. doi: 10.1007/s00404-020-05527-0. Epub 2020 Apr 7.
9
Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.人附睾蛋白4（HE4）、癌抗原125（CA125）与风险卵巢恶性肿瘤算法（ROMA）诊断准确性的比较：一项针对中国上皮性卵巢癌女性患者的前瞻性多中心研究。
Medicine (Baltimore). 2015 Dec;94(52):e2402. doi: 10.1097/MD.0000000000002402.
10
Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.评估人附睾蛋白4（HE4）和卵巢恶性肿瘤风险算法（ROMA）作为日本女性I型和II型上皮性卵巢癌诊断工具的价值。
Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.
引用本文的文献
1
Clinical Value of Combined Multi-Indicator Tests in Diagnosis of Benign Ovarian.联合多项指标检测在卵巢良性病变诊断中的临床价值
Int J Gen Med. 2023 May 29;16:2047-2053. doi: 10.2147/IJGM.S410393. eCollection 2023.
2
Effect of Serum Level of Human Epididymis Protein 4 and Interleukin-6 as Biomarkers in Patients with Adnexal Mass.血清人附睾蛋白 4 和白细胞介素-6 作为附件包块患者生物标志物的效果。
Arch Razi Inst. 2022 Oct 31;77(5):1659-1671. doi: 10.22092/ARI.2022.358329.2194. eCollection 2022 Oct.
3
Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.术前CA125、乳酸脱氢酶和人附睾蛋白4对女性生殖系统平滑肌肉瘤的诊断价值
Cancer Manag Res. 2021 Jun 14;13:4657-4664. doi: 10.2147/CMAR.S302223. eCollection 2021.
4
Level of HE4 is Correlated with Diagnosis of Struma Ovarii: A Case Report.人附睾蛋白4水平与卵巢甲状腺肿的诊断相关：一例报告
Am J Case Rep. 2016 Jul 6;17:459-61. doi: 10.12659/ajcr.897158.
5
Editorial.社论
Afr Health Sci. 2014 Dec;14(4):i-iii. doi: 10.4314/ahs.v14i4.1.
本文引用的文献
1
The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer.使用 HE4、CA125 和 CA72-4 生物标志物进行卵巢子宫内膜异位症和上皮性卵巢癌的鉴别诊断。
J Ovarian Res. 2013 Jul 1;6(1):44. doi: 10.1186/1757-2215-6-44.
2
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.HE4 评估与 CA125 比较在卵巢癌诊断和治疗反应评估中的意义。
Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.
3
Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.人附睾蛋白4、糖类抗原72.4和糖类抗原125在监测卵巢癌中的作用。
Tumour Biol. 2012 Oct;33(5):1335-9. doi: 10.1007/s13277-012-0381-8. Epub 2012 Apr 13.
4
Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women.在子宫内膜异位症患者和健康绝经前妇女中，血清 HE4 浓度不受月经周期或激素治疗的影响。
Gynecol Oncol. 2012 Jun;125(3):667-72. doi: 10.1016/j.ygyno.2012.03.011. Epub 2012 Mar 14.
5
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.在患有良性妇科疾病的女性中，血清 HE4 水平升高的频率低于 CA125。
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8. doi: 10.1016/j.ajog.2011.12.029. Epub 2011 Dec 30.
6
Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.比较人附睾蛋白 4 与癌抗原 125 作为恶性和非恶性疾病患者的肿瘤标志物。
Clin Chem. 2011 Nov;57(11):1534-44. doi: 10.1373/clinchem.2010.157073. Epub 2011 Sep 20.
7
Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.人附睾蛋白 4 在鉴别绝经前女性附件包块的良恶性方面具有更高的特异性。
Am J Obstet Gynecol. 2011 Oct;205(4):358.e1-6. doi: 10.1016/j.ajog.2011.05.017. Epub 2011 May 14.
8
Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.HE4 和 CA125 对各种妇科和非妇科疾病患者卵巢癌的诊断性能。
Clin Biochem. 2011 Jul;44(10-11):884-8. doi: 10.1016/j.clinbiochem.2011.04.011. Epub 2011 Apr 22.
9
HE4 in the differential diagnosis of a pelvic mass: a case report.HE4在盆腔肿块鉴别诊断中的应用：一例病例报告
Int J Mol Sci. 2011 Jan 18;12(1):627-32. doi: 10.3390/ijms12010627.
10
Prognostic significance of HE4 expression in pulmonary adenocarcinoma.HE4表达在肺腺癌中的预后意义。
Tumour Biol. 2011 Apr;32(2):265-71. doi: 10.1007/s13277-010-0118-5. Epub 2010 Oct 15.
Zotero 插件